Galectin Therapeutics (GALT) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kyverna Therapeutics (KYTX) has outperformed Galectin Therapeutics (GALT) over the past year, losing 13.9% versus a loss of 23.2%. Kyverna Therapeutics is the larger company by market cap ($403.2 million vs $384.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GALT | KYTX |
|---|---|---|
| Share price | $3.81 | $6.52 |
| Market cap | $384.24M | $403.22M |
| 1-day change | +4.67% | +5.50% |
| YTD return | -12.50% | -34.26% |
| 1-year return | -23.21% | -13.93% |
| 5-year return | +8.01% | — |
| EPS (TTM) | $-0.43 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.13 | $13.67 |
| 52-week low | $2.03 | $5.96 |
| Distance from 52-week high | -46.56% | -52.30% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +188.71% | +366.26% |
| Average volume | 383.22K | 903.83K |
| Shares outstanding | 100.85M | 61.84M |
| Employees | 9 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
GALT vs KYTX FAQ
Which is bigger, Galectin Therapeutics or Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $403.22M compared with $384.24M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, GALT or KYTX?
KYTX returned -13.93% over the past 12 months, compared with -23.21% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Galectin Therapeutics and Kyverna Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Galectin Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Kyverna Therapeutics.